New cancer chemotherapeutic agents

Cancer

Volumn 30, Issue 6, 1972, Pages 1639-1646

  Burchenal, Joseph H ^a,b   Carter, Stephen K ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 AZAGUANINE; ALDEHYDE; AMIDE; AMINE; ANTINEOPLASTIC AGENT; ASPARAGINASE; AZACITIDINE; BLEOMYCIN; CARMUSTINE; CHLORIDE; CYCLOHEXANE DERIVATIVE; CYTARABINE; CYTIDINE; DOXORUBICIN; GLYCOSIDE; HYDROXYUREA; IMIDAZOLE DERIVATIVE; NITROSOUREA DERIVATIVE; PICOLINIC ACID DERIVATIVE; PLATINUM; PODOPHYLLOTOXIN; STREPTOZOCIN; THIOSEMICARBAZONE DERIVATIVE; TRIAZENE DERIVATIVE;

ANIMAL; CYCLIZATION; HUMAN; LYMPHATIC LEUKEMIA; MOUSE; MYELOID LEUKEMIA; REVIEW;

ALDEHYDES; AMIDES; AMINES; ANIMAL; ANTINEOPLASTIC AGENTS; ASPARAGINASE; AZACITIDINE; AZAGUANINE; BLEOMYCIN; CARMUSTINE; CHLORIDES; CYCLIZATION; CYCLOHEXANES; CYTARABINE; CYTIDINE; DOXORUBICIN; GLYCOSIDES; HUMAN; HYDROXYUREA; IMIDAZOLES; LEUKEMIA, LYMPHOCYTIC; LEUKEMIA, MYELOID; MICE; NITROSOUREA COMPOUNDS; PICOLINIC ACIDS; PLATINUM; PODOPHYLLOTOXIN; STREPTOZOCIN; THIOSEMICARBAZONES; TRIAZENES;

EID: 0015442062     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(197212)30:6<1639::AID-CNCR2820300633>3.0.CO;2-4     Document Type: Article

References (52)

1. Ueber die Chemie neuer zytostatisch wirksamer N‐Chloraethylphosphor‐saeureester‐diamide
2. Bleomycin
3. Therapeutic effects of adriamycin in the neoplastic disease of children and adults
4. Pharmakologische Untersuchungen mit neuen N‐Chloraethylphosphor‐saeureester‐diami‐den
5. Inhibition of ribonucleotide reductase, DNA synthesis and L1210 leukemia by guanazole
6. Evidence that the L‐asparaginase activity of guinea pig serum is responsible for its antilymphoma effects
7. Experimental studies with L‐asparaginase in mouse leukemia
8. Antileukemic and toxic effects of 5‐azacytidine (azaCR)
9. Streptozotocin and metastatic insulinoma
10. 5‐(3,3‐dimethyl‐1‐triazeno)‐imidazole‐4‐carboxamide (DTIC, DIC, NSC‐45388)—a new antitumor agent with activity against malignant melanoma
11. Clinical results of treatment with E. coli L‐asparaginase in adults with leukemia, lymphoma, and solid tumors
12. Antitumor activity in a series of bis‐diketopiperazines
13. Adriamycin (NSC‐123, 127): A new antibiotic with antitumor activity
14. Preliminary clinical trials of the quinazoline antifolate Methasquin
15. Preliminary clinical trials of 5‐hydroxy‐2‐formylpyridine thiosemicarbazone (5‐HP)
16. Immunosuppressive, antiviral, and antitumor activities of cytarabine derivatives
17. Preliminary clinical assessment of ICRF‐159 in acute leukemia and lymphosarcoma
18. Intermittent guanazole (NCS 1895) in the treatment of adult acute leukemia (from the Southwest Cancer Chemotherapy Study Group)
19. Clinical pharmacology of 1‐β‐D‐arabinofuranosyl cytosine (ara‐C)
20. Influence of treatment schedules and route of administration on the chemotherapy of murine leukemia L1210 with 5 (or 4)‐(3,3‐bis[2‐chloroethyl]‐1‐triazeno)‐imidazole‐4(or 5)‐carboxamide (NSC‐82196)
21. E pluribus unum: Presidential address
22. 2,2′‐0‐cyclocytidine, an antitumor cytidine analog resistant to cytidine deaminase
23. Cis‐dichlorodiammineplatinum (II). Persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo
24. Bleomycin treatment of the tumors of penis and scrotum
25. The synthesis of antineoplastic agents. XXXII. N‐nitrosoureas
26. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum or rabbit serum
27. Nucleic acids components and their analogs. LI. Synthesis of 1‐glycosyl derivatives of 5‐azauracil and 5‐azacytidine
28. Platinum compounds: a new class of potent antitumour agents
29. In vivo leukemic cell kill kinetics and “curability” in experimental systems
30. Experimental evaluation of potential anticancer agents. VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia
31. Superiority of 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (NSC 79037) over 1,3‐bis(2‐chloroethyl)‐1‐nitrosourea (NSC 409962) in treatment of advanced Hodgkin's disease
32. Antitumor activity of triazenoimidazoles
33. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules
34. VM 26, a new podophyllotoxin glucoside derivative with anti‐L‐1210 activity
35. E. coli L‐asparaginase in the treatment of leukemia and solid tumors in 131 children
36. Phase I trial of the podophyllotoxin derivative VM‐26
37. Studies on bleomycin
38. New antibiotics, bleomycin A and B
39. Effect of combination treatment with 5‐azacytidine and cytidine on the life‐span and spleen and bone marrow cells of leukemic (L1210) and nonleukemic mice
40. The treatment of brain tumor with 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU)
41. Clinical trial of bleomycin